Related Experiment Video
Updated: Jun 1, 2026
A Modified Simple Method for Induction of Myocardial Infarction in Mice
Published on: December 3, 2021
Insulin-Like Growth Factor-1 (IGF-1) Reduces ischemic changes and increases circulating angiogenic factors in
Mathews Lisa1, Nagaraja Haleagrahara1, Srikumar Chakravarthi2
1Division of Human Biology, Faculty of Medicine, International Medical University, Kuala Lumpur, 57000, Malaysia.
Background:
Coronary artery disease is a global health concern in the present day with limited therapies. Extensive efforts have been devoted to find molecular therapies to enhance perfusion and function of the ischemic myocardium. Aim of the present study was to look into the effects of insulin like growth factor -1 (IGF-1) on circulating angiogenic factors after myocardial ischemia in rats.
Methods:
Adult male Sprague-Dawley rats were randomly divided into 10-days control, myocardial infarction, IGF-1 alone (2 μg/rat/day) and ISO+IGF-1 groups. Isoproterenol (ISO), a synthetic catecholamine was used to induce myocardial infarction. Serum transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) levels were checked after 10-days of IGF-1 administration.
Results:
There was a significant increase in heart weight after IGF-1 treatment. A significant increase in cardiac enzyme level (CK-MB and LDH) was seen in isoproterenol treated rats when compared to control group. IGF-1treatment induced a significant increase in serum angiogenic factors, IGF-1, VEGF and TGF beta levels. IGF-1 also reduced the ischemic changes in the myocardium when compared to the isoproterenol alone treated group.
Conclusions:
In conclusion, treatment with insulin-like growth factor-1 (IGF-1) in myocardial infarction significantly increased circulating angiogenic growth factors like IGF-1, VEGF and TGF beta thus, protecting against myocardial ischemia.
Insights
Insulin-like growth factor-1 (IGF-1) treatment in rats with myocardial infarction significantly boosted circulating angiogenic factors, including IGF-1, VEGF, and TGF-beta, offering protection against cardiac ischemia.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Regenerative Medicine
Background:
- Coronary artery disease presents a global health challenge with limited therapeutic options.
- Research focuses on molecular therapies to improve blood flow and function in ischemic heart tissue.
- Investigating the role of insulin-like growth factor-1 (IGF-1) in modulating angiogenic factors post-myocardial infarction.
Purpose of the Study:
- To evaluate the impact of IGF-1 on circulating angiogenic factors in a rat model of myocardial ischemia.
- To assess the therapeutic potential of IGF-1 in mitigating cardiac damage.
Main Methods:
- Adult male Sprague-Dawley rats were assigned to control, myocardial infarction, IGF-1 alone, or ISO+IGF-1 groups.
- Myocardial infarction was induced using isoproterenol (ISO).
- Serum levels of transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) were measured after 10 days of IGF-1 administration.
Main Results:
- IGF-1 treatment led to a significant increase in heart weight.
- Isoproterenol induced significant increases in cardiac enzymes (CK-MB, LDH).
- IGF-1 administration significantly elevated serum levels of IGF-1, VEGF, and TGF-beta, and reduced myocardial ischemic damage.
Conclusions:
- IGF-1 treatment in myocardial infarction models significantly enhances circulating angiogenic factors (IGF-1, VEGF, TGF-beta).
- IGF-1 demonstrates protective effects against myocardial ischemia.
- This suggests IGF-1 as a potential therapeutic agent for ischemic heart conditions.
